The role of macrophage-derived urokinase plasminogen activator in myocardial infarct repair. Urokinase attenuates ventricular remodeling

Journal of Molecular and Cellular Cardiology

Volumn 49, Issue 3, 2010, Pages 516-524

  Minami, Elina ^a   Castellani, Chiara ^b   Malchodi, Laura ^a   Deem, Jennifer ^c   Bertko, Kate ^a   Meznarich, Jessica ^a   Dishmon, Monja ^c   Murry, Charles E ^c   Stempien Otero, April ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Collagen; Inflammation; Macrophage; Plasminogen; Remodeling

Indexed keywords

COLLAGEN; COLLAGEN TYPE 1; PLASMIN; UROKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART CONTRACTION; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; MACROPHAGE ACTIVATION; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WILD TYPE;

MUS;

EID: 77955270731     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.03.022     Document Type: Article

References (30)

1. Weisman H.F., Bush D.E., Mannisi J.A., Weisfeldt M.L., Healy B. Cellular mechanisms of myocardial infarct expansion. Circulation Jul 1988, 78(1):186-201.
2. Whittaker P., Boughner D.R., Kloner R.A. Role of collagen in acute myocardial infarct expansion. Circulation Nov 1991, 84(5):2123-2134.
3. Olivetti G., Capasso J.M., Sonnenblick E.H., Anversa P. Side-to-side slippage of myocytes participates in ventricular wall remodeling acutely after myocardial infarction in rats. Circ Res Jul 1990, 67(1):23-34.
4. Dewald O., Zymek P., Winkelmann K., Koerting A., Ren G., Abou-Khamis T., et al. CCL2/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res Apr 29 2005, 96(8):881-889.
5. Tyagi S., Kumar S., Haas S., Reddy H., Voelker D., Hayden M., et al. Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. J Mol Cell Cardiol 1996, 28:1415-1428.
6. Gaertner R., Jacob M.P., Prunier F., Angles-Cano E., Mercadier J.J., Michel J.B. The plasminogen-MMP system is more activated in the scar than in viable myocardium 3months post-MI in the rat. J Mol Cell Cardiol Jan 2005, 38(1):193-204.
7. Knoepfler P.S., Bloor C.M., Carroll S.M. Urokinase plasminogen activator activity is increased in the myocardium during coronary artery occlusion. J Mol Cell Cardiol Jun 1995, 27(6):1317-1324.
8. Heymans S., Luttun A., Nuyens D., Theilmeier G., Creemers E., Moons L., et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but imparis therapeutic angiogenesis and causes cardiac failure. Nat Med 1999, 5:1135-1142.
9. Creemers E., Cleutjens J., Smits J., Heymans S., Moons L., Collen D., et al. Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. Am J Pathol Jun 2000, 156(6):1865-1873.
10. Ramos-DeSimone N., Hahn-Dantona E., Sipley J., Nagase H., French D.L., Quigley J.P. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem May 7 1999, 274(19):13066-13076.
11. Monea S., Lehti K., Keski-Oja J., Mignatti P. Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J Cell Physiol Aug 2002, 192(2):160-170.
12. Vanhoutte D., Schellings M., Pinto Y., Heymans S. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res Feb 15 2006, 69(3):604-613.
13. Parks W.C., Wilson C.L., Lopez-Boado Y.S. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol Aug 2004, 4(8):617-629.
14. Matsusaka H., Ide T., Matsushima S., Ikeuchi M., Kubota T., Sunagawa K., et al. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension Apr 2006, 47(4):711-717.
15. Van Linthout S., Seeland U., Riad A., Eckhardt O., Hohl M., Dhayat N., et al. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol Jul 2008, 103(4):319-327.
16. Fert-Bober J., Leon H., Sawicka J., Basran R.S., Devon R.M., Schulz R., et al. Inhibiting matrix metalloproteinase-2 reduces protein release into coronary effluent from isolated rat hearts during ischemia-reperfusion. Basic Res Cardiol Sep 2008, 103(5):431-443.
17. Moriwaki H., Stempien-Otero A., Kremen M., Cozen A.E., Dichek D.A. Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice. Circ Res Sep 17 2004, 95(6):637-644.
18. Stempien-Otero A., Plawman A., Meznarich J., Dyamenahalli T., Otsuka G., Dichek D.A. Mechanisms of cardiac fibrosis induced by urokinase plasminogen activator. J Biol Chem Jun 2 2006, 281(22):15345-15351.
19. Cozen A.E., Moriwaki H., Kremen M., DeYoung M.B., Dichek H.L., Slezicki K.I., et al. Macrophage-targeted overexpression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death. Circulation May 4 2004, 109(17):2129-2135.
20. Haudek S.B., Xia Y., Huebener P., Lee J.M., Carlson S., Crawford J.R., et al. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc Natl Acad Sci U S A Nov 28 2006, 103(48):18284-18289.
21. Rossow C.F., Minami E., Chase E.G., Murry C.E., Santana L.F. NFATc3-induced reductions in voltage-gated K+ currents after myocardial infarction. Circ Res May 28 2004, 94(10):1340-1350.
22. Reinecke H., Murry C.E. Cell grafting for cardiac repair. Methods Mol Biol 2003, 219:97-112.
23. Gregorevic P., Allen J.M., Minami E., Blankinship M.J., Haraguchi M., Meuse L., et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med Jul 2006, 12(7):787-789.
24. Murtuza B., Suzuki K., Bou-Gharios G., Beauchamp J.R., Smolenski R.T., Partridge T.A., et al. Transplantation of skeletal myoblasts secreting an IL-1 inhibitor modulates adverse remodeling in infarcted murine myocardium. Proc Natl Acad Sci U S A Mar 23 2004, 101(12):4216-4221.
25. Bujak M., Dobaczewski M., Chatila K., Mendoza L.H., Li N., Reddy A., et al. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol Jul 2008, 173(1):57-67.
26. van Amerongen M.J., Harmsen M.C., van Rooijen N., Petersen A.H., van Luyn M.J. Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice. Am J Pathol Mar 2007, 170(3):818-829.
27. Frangogiannis N.G., Dewald O., Xia Y., Ren G., Haudek S., Leucker T., et al. Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy. Circulation Feb 6 2007, 115(5):584-592.
28. Nahrendorf M., Swirski F.K., Aikawa E., Stangenberg L., Wurdinger T., Figueiredo J.L., et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med Nov 26 2007, 204(12):3037-3047.
29. Frantz S., Hu K., Adamek A., Wolf J., Sallam A., Maier S.K., et al. Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol Sep 2008, 103(5):485-492.
30. Ra H.J., Parks W.C. Control of matrix metalloproteinase catalytic activity. Matrix Biol Oct 2007, 26(8):587-596.